D. Hu-Lowe

发表

Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor‐receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast‐enhanced MRI

N. Hylton, R. Henry, R. Brasch, 2005, Journal of magnetic resonance imaging : JMRI.

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Gavin Thurston, G. Yancopoulos, D. McDonald, 2004, The American journal of pathology.

Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor.

T. Tuthill, K. Ferrara, D. Hu-Lowe, 2011, Ultrasound in medicine & biology.

A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition

E. Kraynov, S. Bergqvist, D. Hu-Lowe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

R. Simon, W. Levin, A. Erbersdobler, 2011, Cancer research.

78 POSTER Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models

J. Christensen, D. McDonald, B. Sennino, 2006 .

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

C. Kuo, D. McDonald, G. Thurston, 2006, American journal of physiology. Heart and circulatory physiology.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

P. Zarrinkar, K. Yu, D. Brehmer, 2018, Cell.

Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting*

M. Goumans, P. ten Dijke, S. Bergqvist, 2012, The Journal of Biological Chemistry.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

D. McDonald, T. Inai, B. Sennino, 2006, The Journal of clinical investigation.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006, Molecular Cancer Therapeutics.

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

J. Christensen, A. Stewart, D. Hu-Lowe, 2010, Cancer research.

SU 14813 : a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006 .

Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

C. Kuo, D. McDonald, B. Sennino, 2009, Cancer research.

Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.

D. McDonald, D. Hu-Lowe, D. Shalinsky, 2006, Cancer research.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

P. O'Connor, M. McTigue, S. Yamazaki, 2008, Clinical Cancer Research.

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

S. Bender, Lianglin Zhang, S. Bergqvist, 2010, Cancer research.

Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.

Alberto D'Onofrio, A. d’Onofrio, Y. Shaked, 2011, Drug discovery today.

Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.

R. Weissleder, A. Bogdanov, D. Hu-Lowe, 2005, Neoplasia.

AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo.

D. McConkey, A. Siefker-Radtke, D. Hu-Lowe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Ying Lu, Ka-Loh Li, Roland G Henry, 2007, Magnetic resonance imaging.

Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.

I. Kasman, W. You, D. McDonald, 2010, The American journal of pathology.

Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors

K. Yu, Tao Wu, F. Burrows, 2017 .

Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.

Y. R. Kim, R. Weissleder, A. Bogdanov, 2005, Cancer research.

The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies

D. Hu-Lowe, N. Brega, S. Patyna, 2011, Molecular Cancer Therapeutics.

Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

C. Kuo, D. McDonald, B. Sennino, 2009, Cancer research.

A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition

E. Kraynov, S. Bergqvist, D. Hu-Lowe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Tumorigenesis and Neoplastic Progression Ricinus communis Agglutinin I Leads to Rapid Down-Regulation of VEGFR-2 and Endothelial Cell Apoptosis in Tumor Blood Vessels

I. Kasman, W. You, D. Hu-Lowe, 2010 .

Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF-03446962 undergoing phase I trial in cancer patients.

F. Bertolini, D. Hu-Lowe, D. Shalinsky, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.